Daily Roundup

Vysarn Terminates NewGround Acquisition

Vysarn Limited has decided to walk away from its proposed acquisition of NewGround. The two parties mutually agreed not to extend the completion date beyond October 2, 2026, which effectively ended the deal. The share sale agreement will now be terminated, and the acquisition won't proceed. Vysarn is turning its attention to exploring other strategic opportunities moving forward.

Synertec Lands Major $45.5m Nuclear Medicine Contract

In a significant win for the engineering sector, Synertec Corporation has secured a $45.5 million contract from the Australian Nuclear Science and Technology Organisation (ANSTO). The project involves designing and integrating a new Nuclear Medicine Manufacturing Facility at Lucas Heights in New South Wales as part of ANSTO's Nuclear Medicine Manufacturing Program. Synertec will handle process design and integration while ensuring compliance with strict pharmaceutical and regulatory standards. The deal is expected to be a major revenue driver for the company, with approximately $36 million recognized during the initial 26-month design phase. Beyond the financial boost—the contract is worth over 2.4 times Synertec's FY26 revenue—the project will strengthen Australia's sovereign capability in nuclear medicine manufacturing and help secure long-term supply of critical healthcare products. The company plans to update its FY27 revenue guidance once the project execution profile becomes clearer.

Telix Scores FDA Approval for Brain Cancer Imaging Drug

Telix Pharmaceuticals has achieved a major milestone with FDA approval for Pixclara, a groundbreaking imaging drug for gliomas. This is the first FDA-approved FET-PET imaging drug on the market, addressing a significant gap in brain cancer diagnostics. Pixclara helps physicians distinguish between recurrent or progressive gliomas and treatment-related changes—a critical distinction that was previously difficult to make. The approval reinforces Telix's leadership in precision medicine and expands its portfolio in diagnostics and targeted radiopharmaceutical therapies.

NRW Holdings Secures Major Project Awards

NRW Holdings' subsidiaries have landed substantial contracts. Primero Group won the Ramelius Resources Mount Magnet Expansion Project, valued at approximately $313 million, which will involve upgrading processing infrastructure to support ore integration and production hub expansion. Meanwhile, NRW Contracting was awarded Optional Works for the Tonkin Highway Grade Separations project by Main Roads Western Australia, bringing that contract's total value to around $300 million. These wins strengthen NRW's position as a leading engineering, procurement, and construction contractor in the Australian resources sector.

Titomic Wins $5m U.S. Air Force Contract

Cold spray manufacturing specialist Titomic has secured a $5 million contract from the U.S. Air Force. The company's U.S. subsidiary will supply, integrate, and commission a Next Generation Titomic Kinetic Fusion High Pressure Cold Spray System at Tinker Air Force Base. The advanced system will feature industrial robotic automation, powder and gas management, process monitoring, and real-time quality verification capabilities. It's designed for depot-level manufacturing and sustainment applications, including component repair, corrosion protection, and additive manufacturing. Delivery is scheduled for the third quarter of 2027.